ICER special report on Eliquis and Xarelto cost efficiencies

US health technology assessor the Institute for Clinical and Economic Review (ICER) today posted a  Special Report evaluating the evidence on US pharma major Bristol Myers Squibb’s (NYSE: BMY) Eliquis (apixaban) and German drugmaker Bayer’s (BAYN: DE) Xarelto (rivaroxaban) for the treatment of non-valvular atrial fibrillation (NVAF).

“The US is beginning a new era in which the federal government will engage in negotiating drug pricing,” said the ICER’s president Dr Steven Pearson.

He noted that, in this task, the Centers for Medicare & Medicaid Services (CMS) faces the challenge of evaluating a large evidence base and of integrating considerations regarding unmet need and other factors to arrive at price targets for negotiation.